MDL Statistics November 2026: Uber's Pending Count Falls 368 as Social Media MDL Adds 485

The Judicial Panel on Multidistrict Litigation's MDL statistics for November 2026, in a report dated November 2, list 164 pending dockets, and Johnson & Johnson's talc litigation is still the largest with 69,376 pending actions. The headline movement ran in opposite directions: Uber's sexual assault MDL shed 368 pending cases even as new filings arrived, while the social media adolescent addiction MDL added 485 and Bard's port catheter MDL added 205.

The JPML's monthly report is the closest thing the federal judiciary publishes to a census of mass tort litigation, and it is the figure that plaintiffs' firms, defense counsel, insurers and litigation funders quote when they size a docket. This analysis compares the November figures with the October 1, 2026 report docket by docket, adds the history-total column that most trackers drop, works out how many cases actually left each docket, and ties each number to where the litigation now stands. Two figures in the November report do not reconcile cleanly with October's, and this article says so instead of printing them silently.

MDL statistics November 2026: the headline numbers

The Judicial Panel on Multidistrict Litigation (JPML) publishes its pending-MDL statistics on the first business day of each month. November 1, 2026 fell on a Sunday, so the November edition carries a report date of Monday, November 2, 2026. Like every edition, it is issued in several sorts (by district, by MDL number, by docket type and by actions pending); the actions-pending sort ranks every open Multidistrict Litigation (MDL) from largest to smallest and is the version most trackers rely on.

The November report shows:

• 164 MDL dockets pending, up from 162 on October 1, 2026.
• J&J talc (MDL 2738) at 69,376 pending actions, nearly three times the next-largest docket.
• A top five unchanged in order (talc, hernia mesh, AFFF, hair relaxer, proton-pump inhibitors) holding 132,092 pending actions between them, up 379 from 131,713 in October.

The two-docket increase has an identifiable cause. On October 2, 2026, the Panel issued separate transfer orders creating MDL No. 3194 for Abbott spinal cord stimulator cases, assigned to Judge Lindsay C. Jenkins in the Northern District of Illinois, and MDL No. 3195 for Nevro cases, assigned to Judge Haywood S. Gilliam Jr. in the Northern District of California. Those orders came one day after the October report date, so November is the first edition in which either docket can appear. Each started small: Bloomberg Law reported at the time that Abbott faced 26 pending federal suits and Nevro 23. A net change of two dockets is consistent with those two creations and no terminations in the month, though the report's list of terminated MDLs was not available to this desk to confirm it.

A national pending total for November could not be verified. One tracker gives a figure of 204,977, but it compares that number to a "previous month" total of 206,182, which is actually the verified September 1 total; because the comparison is off by a month, the figure is not used here. The analysis below therefore works from the docket-level rows, which are the numbers that matter for any particular litigation.

How many MDLs are pending in November 2026?

There are 164 pending MDL dockets in the JPML's November 2, 2026 report, two more than the 162 listed on October 1, 2026. The increase reflects the Panel's October 2 creation of MDL No. 3194 (Abbott spinal cord stimulators, N.D. Ill.) and MDL No. 3195 (Nevro spinal cord stimulators, N.D. Cal.).

The count reverses a recent trend. Between September and October the system went from 166 dockets to 162 as long-running proceedings were closed out. A docket count is a weak measure of mass tort activity on its own, because a single MDL can hold 70,000 actions and another can hold six. What the count does show is the Panel's appetite for centralization. Its June 2026 refusal to create a single, industry-wide spinal cord stimulator MDL, followed by its October decision to create manufacturer-specific dockets, is a reminder that the Panel will centralize when defendants, products and regulatory histories line up, and will not when they do not. Medtronic stimulator claims remain outside any MDL, and Boston Scientific's are in a separate docket, MDL No. 3181, before Judge Josephine L. Staton in the Central District of California.

What is the largest MDL in November 2026?

The largest MDL in November 2026 is In re: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation, MDL No. 2738, in the District of New Jersey, with 69,376 pending actions out of 72,060 filed. It added 36 actions in the month, and its history total also rose by 36, so no talc case left the federal docket between the two reports.

The top five dockets on November 2, 2026:

Rank	MDL No.	Litigation	District	Pending Nov. 2	History total	Pending Oct. 1	Change	Pending share of history
1	2738	J&J talcum powder	D.N.J.	69,376	72,060	69,340	+36	96.3%
2	2846	Davol / C.R. Bard polypropylene hernia mesh	S.D. Ohio	23,299	25,224	23,324	-25	92.4%
3	2873	Aqueous film-forming foams (AFFF)	D.S.C.	15,270	19,846	15,264	+6	76.9%
4	3060	Hair relaxer	N.D. Ill.	12,743	17,018	12,381	+362	74.9%
5	2789	Proton-pump inhibitors	D.N.J.	11,404	18,755	11,404	0	60.8%

The last column is derived by this desk, not printed by the Panel. A docket where almost every case ever filed is still open has resolved very little; a docket where the share has dropped well below 100 percent has already shed cases through settlement, dismissal or remand.

Talc's flat month is a function of where the litigation sits. Johnson & Johnson's July 27, 2026 proposal commits $5.5 billion to resolve roughly 76,000 remaining ovarian cancer claims, conditioned on express participation by lead plaintiff firms representing at least 95 percent of them. Lead counsel told a federal magistrate judge in October that 313 firms representing about 66,500 claimants, around 87.5 percent, had signed on, as Law.com reported on October 19. The district court has held MDL deadlines in abeyance while the participation drive runs, and plaintiffs face a November 19, 2026 deadline to respond to Magistrate Judge Rukhsanah L. Singh's July 22 show-cause order on Specific Causation if the threshold is not met or waived. With a conditional deal on the table and a show-cause order in the background, few firms have reason to pay to file new federal talc cases this month.

The talc number also tells only half the story of J&J's exposure. Mesothelioma claims, which the ovarian proposal does not cover, are tried in state courts; on November 6, 2026, a Suffolk County, Massachusetts jury found J&J talc caused former nurse Winifred Haddad's mesothelioma and awarded roughly $1.9 million. None of those state cases appear in the JPML figures.

The proton-pump inhibitor row is identical in both months: 11,404 pending and 18,755 in history. That is possible for a docket in its late stage with no new filings and no terminations, but it is also what a carried-over row would look like. Without direct access to the PDF, this desk reports the row as unchanged and flags that the identical match should be checked against the report itself.

Why did the Uber sexual assault MDL case count drop in November 2026?

The Uber MDL's pending count dropped because about 699 actions were terminated between the October and November reports while 331 new actions were added. MDL No. 3084, In re: Uber Technologies, Inc., Passenger Sexual Assault Litigation, before Judge Charles R. Breyer in the Northern District of California, went from 4,916 pending out of 5,221 filed on October 1, 2026 to 4,548 pending out of 5,552 filed on November 2.

The arithmetic matters because a falling pending number is easy to misread as falling interest. It is the opposite. The history total, which only goes up, grew by 331 actions in a month, roughly in line with the 328-case gain in pending actions between September and October. What changed is the exit rate. The difference between the history increase (+331) and the pending change (-368) puts terminations at about 699 actions, by far the largest exit of any major personal injury docket in the month.

The JPML report does not say why cases leave a docket, but the record supplies a likely explanation. Uber told the court in late July 2026 that 972 federal claims and 379 California state-court claims were subject to pending settlement agreements. Under an inventory settlement, cases stay "pending" on the JPML's books until stipulations of dismissal are actually filed. A surge of dismissals as those agreements are performed would produce exactly the November pattern: new filings continuing at their recent pace while the pending count falls. Remands to transferor courts would also reduce the count, but no remand wave has been reported in MDL 3084.

The federal bellwether program has been unpredictable. The Dean bellwether in February 2026 produced an $8.5 million plaintiff verdict; the Mensing trial on April 20, 2026 produced a $5,000 verdict; and the third federal bellwether, tried in the Western District of Texas with Judge Breyer presiding, settled on confidential terms announced October 2, 2026, after a jury had been seated. No global settlement has been announced, and claims pending in the parallel California Judicial Council Coordination Proceeding are not part of the JPML count.

For anyone valuing Uber inventory, the lesson is that the pending figure now understates filing momentum and overstates what remains to be tried, at the same time. Both history total and pending count need to be read together.

Which MDLs grew the most between October and November 2026?

Among the major personal injury dockets for which both months' figures could be verified, the social media adolescent addiction MDL grew the most between October and November 2026, adding 485 pending actions. Hair relaxer was second on its reported pending figure (+362), followed by Bard's implanted port catheter MDL (+205), GLP-1 gastrointestinal claims (+57), talc (+36), paraquat (+33) and GLP-1 vision-loss claims (+31).

MDL No.	Litigation	Pending Oct. 1	Pending Nov. 2	Change	History Nov. 2	Procedural stage, November 2026
3047	Social media adolescent addiction	3,824	4,309	+485	4,495	California JCCP bellwether settled Nov. 2; federal school-district track active
3060	Hair relaxer	12,381	12,743	+362	17,018	Lead epidemiologist survived Rule 702 Oct. 22; first trial Sept. 2027
3081	Bard implanted port catheter	4,140	4,345	+205	not verified	Defense verdict Oct. 30; fourth bellwether Dec. 1
3094	GLP-1 RAs (gastrointestinal)	4,025	4,082	+57	4,196	Rule 702 general causation ruling pending
2738	J&J talc	69,340	69,376	+36	72,060	95% participation drive; Nov. 19 show-cause response
3004	Paraquat	6,602	6,635	+33	8,529	Master settlement holdouts in limited discovery
3163	GLP-1 RAs (NAION vision loss)	247	278	+31	278	Cross-cutting schedule; expert challenges due July 2027
2873	AFFF	15,264	15,270	+6	19,846	3M $7.35 billion PI deal announced Nov. 3
3140	Depo-Provera	6,412	6,413	+1	6,525	Settlement registration expected to close in November
3092	Suboxone film	2,022	2,016	-6	2,129	Bellwethers not before end of Q1 2028
2846	Bard/Davol hernia mesh	23,324	23,299	-25	25,224	Late-stage docket; small net exits
3084	Uber sexual assault	4,916	4,548	-368	5,552	~699 actions terminated; inventory settlements

The pattern across the table is consistent with the rule of thumb that filings follow procedural signals. The dockets that grew are those where a recent ruling or trial gave plaintiffs' firms a reason to keep investing (hair relaxer's expert ruling, PowerPort's $40 million September verdict, the social media trials). The dockets that stalled are those where a settlement framework has redirected claimants (Depo-Provera, AFFF, talc) or where a single gatekeeping ruling is pending.

How many social media addiction lawsuits are pending in MDL 3047?

MDL No. 3047, In re: Social Media Adolescent Addiction/Personal Injury Products Liability Litigation, before Judge Yvonne Gonzalez Rogers in the Northern District of California, lists 4,309 pending actions out of 4,495 filed in the November 2, 2026 report. That is up 485 from 3,824 on October 1, and the October figure was itself a jump of more than 600 from September.

The federal docket is now growing faster than any other major personal injury MDL, and it is doing so while the defendants settle individual trials one at a time. In the coordinated California state proceeding, JCCP 5255 before Judge Carolyn B. Kuhl in Los Angeles County Superior Court, the second individual bellwether collapsed before openings: TikTok settled with both plaintiffs in August, YouTube on September 25, Meta on October 30, and Snap on November 2, 2026. The only jury result in the California cases remains the $6 million K.G.M. verdict of March 25, 2026 against Meta and YouTube, which is on appeal. The next JCCP bellwethers are set for March 16, 2027 and August 6, 2027.

In the federal MDL, the school-district track has also produced settlements, including Snap's resolution of the Breathitt County, Kentucky school district case. Meta's separate multistate attorney general settlement, reported at up to $17.1 billion and entered by a court on August 26, 2026, resolves government claims, not individual personal injury claims.

Two cautions apply to the 3047 count. First, the MDL contains both personal injury actions and school-district and local-government actions, and the JPML report does not separate them. Second, the much larger body of California claims (more than 3,300 in JCCP 5255, by published accounts) sits entirely outside the federal number. The 485-case gain reflects federal filings only.

How many hair relaxer lawsuits are pending in November 2026?

The November 2, 2026 JPML report lists 12,743 pending actions out of 17,018 filed in MDL No. 3060, In re: Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation, before Judge Mary M. Rowland in the Northern District of Illinois. On its face that is a gain of 362 from 12,381 on October 1.

That headline figure comes with a reconciliation problem. The October report showed a history total of 16,828, which means the history total rose by 190 in the month while the pending count rose by 362. In a normal month, pending actions cannot rise by more than the number of new actions added, because every new case is counted in both columns. A pending increase larger than the history increase points to one of three things: reinstated or reopened cases, a correction to a prior month's count, or a transcription error in one of the two reports. This desk could not resolve which from the sources available, so the safest statement is that hair relaxer is somewhere between 12,571 and 12,743 pending actions on a like-for-like basis, and growing either way.

The direction of travel is clear regardless. On October 22, 2026, Judge Rowland denied the defendants' motion to exclude the plaintiffs' lead epidemiologist, Dr. Cote, whose opinion is that chemical hair relaxers can cause uterine and ovarian cancer, and granted the motion only in part as to a second General Causation expert. The parties fixed the final five Bellwether Trial cases the same day, including the only ovarian cancer case, ahead of a first trial set for September 2027. Minnesota's attorney general sued L'Oréal and SoftSheen-Carson in Hennepin County on October 23, following Arizona's September suit. A favorable expert ruling of that kind is exactly the signal that pushes firms holding unfiled inventory to file.

How many Ozempic and GLP-1 lawsuits are pending in November 2026?

There are 4,082 pending actions in MDL No. 3094, the GLP-1 receptor agonist gastrointestinal-injury docket before Judge Karen Spencer Marston in the Eastern District of Pennsylvania, out of 4,196 filed, according to the November 2, 2026 report. A separate vision-loss docket, MDL No. 3163, covering non-arteritic anterior ischemic optic neuropathy (NAION) claims and assigned to the same judge, lists 278 pending actions, all 278 ever filed.

Both GLP-1 dockets grew in the month (+57 and +31), after the gastrointestinal docket had been nearly flat between September and October. The increase comes while the gastrointestinal litigation's central question remains undecided. Judge Marston held a Rule 702 hearing in September 2026 on whether the plaintiffs' experts may testify that the drugs cause gastroparesis, ileus and bowel obstruction, and set closing arguments on the pending motions for October 13. No ruling had been reported as of this report. She had already held, in August 2025, that a gastroparesis claim requires a gastric emptying study performed at the time of diagnosis, a requirement that screens out many potential claimants before causation is reached.

The NAION docket's 100 percent pending share reflects its age. The Panel created MDL 3163 on December 15, 2025, and its own cross-cutting schedule does not reach expert challenges until July 2, 2027. The gastrointestinal Daubert Challenge will not decide the vision-loss claims, which is one reason firms are willing to keep filing them while MDL 3094 waits.

Bard PowerPort, Depo-Provera, paraquat, AFFF and Suboxone: what moved and why

Bard implanted port catheters (MDL 3081). The docket before Judge David G. Campbell in the District of Arizona rose from 4,140 to 4,345 pending actions. The gain came in the same month Bard won its second bellwether. A federal jury returned a defense verdict on October 30, 2026 in Lattanzio, an infection case, after a defense result in Cook in May and a $40 million compensatory verdict for the plaintiff in Divelbliss, a fracture case, on September 4. Bard has moved for a new trial in Divelbliss. The fourth bellwether, Hicks, is set for December 1, 2026 and the fifth, Sorensen, for February 2, 2027. Firms appear to be filing on the strength of the September verdict rather than retreating after October's defense win, which is typical: a single large plaintiff verdict tends to drive intake for months.

Bellwether	Injury theory	Result	Date
Cook	Infection	Defense result	May 2026
Divelbliss	Fracture	$40 million compensatory, no punitive damages	Sept. 4, 2026
Lattanzio	Infection	Defense verdict	Oct. 30, 2026
Hicks	Thrombosis	Set for trial	Dec. 1, 2026
Sorensen	To be tried	Set for trial	Feb. 2, 2027

Depo-Provera (MDL 3140). The docket before Judge M. Casey Rodgers in the Northern District of Florida moved by a single action, to 6,413 pending out of 6,525 filed. Pfizer and plaintiffs' leadership signed a Master Settlement Agreement on July 21, 2026, BrownGreer was appointed settlement administrator on August 5, and registration has been expected to close in November 2026, with first payments projected for early 2027. A one-case month is what a docket looks like once claims are being routed into a program rather than filed as new federal actions. The next status conference is set for November 20.

Paraquat (MDL 3004). The docket before Chief Judge Nancy J. Rosenstengel in the Southern District of Illinois rose by 33 to 6,635 pending out of 8,529 filed. Syngenta and Chevron signed a Master Settlement Agreement in 2025, and more than 900 plaintiffs have since rejected individual offers; those holdouts are in limited discovery and still face the April 2024 exclusion of the plaintiffs' only general causation expert. The history total rose by 34, so the docket is still taking in new cases despite the settlement.

AFFF (MDL 2873). The docket before Judge Richard M. Gergel in the District of South Carolina rose by six, to 15,270 pending out of 19,846 filed. The report predates the news that matters: on November 3, 2026, one day after the report date, 3M announced a $7.35 billion nominal commitment over nine years (present value $5.8 billion) to resolve roughly 99 percent of current PFAS personal injury claims, with about 115,000 to 120,000 plaintiffs eligible. Most of those plaintiffs are not separate federal actions; the AFFF docket's JPML count includes water-provider and government cases, and many injury claimants are on multi-plaintiff complaints or unfiled. The 3M deal will show in the JPML figures only as dismissals are entered, which on the settlement's timetable will take months. Judge Gergel's Case Management Order 39 sets a November 13, 2026 deadline to identify all eligible 3M claimants.

Suboxone film (MDL 3092). The docket before Judge J. Philip Calabrese in the Northern District of Ohio fell by six to 2,016 pending, while its history total rose by 17 to 2,129. This is the clearest example of how far a JPML action count can sit from the number of people suing. Indivior's quarterly report for the period ending September 30, 2026 said about 1,925 cases naming roughly 22,098 plaintiffs were consolidated in the MDL as of October 23, 2026, down from about 26,307 plaintiffs three months earlier. Indivior says bellwether trials would not occur until the end of the first quarter of 2028 at the earliest.

Hernia mesh (MDL 2846). The Davol / C.R. Bard docket before Judge Edmund A. Sargus Jr. in the Southern District of Ohio fell by 25 to 23,299 pending while adding seven new actions, so about 32 cases left. At eight years old it is a slow-moving docket where small monthly exits are the norm.

What the history-total column reveals: terminations by docket

Most monthly trackers print only the pending figure. Pairing it with the history total produces a third number, the actions that left the docket during the month, calculated as the history increase minus the pending change. It is an approximation, because the JPML does not report terminations by month, but it is a useful one.

MDL No.	Litigation	History change	Pending change	Implied actions terminated
3084	Uber sexual assault	+331	-368	about 699
2846	Bard/Davol hernia mesh	+7	-25	about 32
3092	Suboxone film	+17	-6	about 23
3004	Paraquat	+34	+33	about 1
2738	J&J talc	+36	+36	0
2873	AFFF	+6	+6	0
3094	GLP-1 RAs	+57	+57	0
3140	Depo-Provera	+1	+1	0
3060	Hair relaxer	+190	+362	does not reconcile

Three readings follow. Uber's exit rate is the outlier of the month by an order of magnitude. Several of the largest settlement-stage dockets (talc, AFFF, Depo-Provera) recorded zero terminations, which means none of those settlements has yet translated into a wave of federal dismissals; the pending counts will fall only once releases are signed and stipulations filed. And hair relaxer's row should be treated with caution until the November and October reports can be reconciled.

Does the JPML count include every mass tort claim?

No. The JPML report counts civil actions on federal MDL dockets, not claimants, and it omits every claim that has not been filed as a federal action. A multi-plaintiff complaint counts once, claims preserved under a Tolling Agreement or a Census Registry do not appear at all, and state coordinated proceedings are entirely outside the count.

The November figures show the size of the gap in concrete terms:

• Suboxone: 2,016 pending federal actions, but about 22,098 named plaintiffs according to the defendant's own securities filing.
• AFFF: 15,270 pending actions, against roughly 115,000 to 120,000 personal injury plaintiffs eligible for 3M's settlement.
• Talc: 69,376 federal actions, against roughly 76,000 remaining ovarian claims in state and federal court combined, plus mesothelioma claims tried in state courts.
• Social media: 4,309 federal actions, with more than 3,300 further cases in California's JCCP 5255.

Settled-but-undismissed cases cut the other way, keeping the pending figure higher than the live inventory until paperwork catches up, as the Uber docket showed in reverse this month. The JPML count is best treated as a floor for claimant volume in registry-heavy and state-heavy litigations, and as a ceiling for the cases that genuinely remain to be tried in dockets with inventory settlements.

What MDL statistics November 2026 mean for practitioners

For personal injury firms

The November MDL statistics reward reading the procedural stage before the number. Hair relaxer and the social media MDL are the dockets with the clearest intake momentum, and both have recent rulings or trial events behind them; both also have first federal trials that are months away, so the cost of carrying inventory to trial is real. Bard PowerPort continues to attract filings after a mixed bellwether record, which places weight on case selection by injury theory: the plaintiff verdict was a fracture case, and both defense results were infection cases. In GLP-1, new gastrointestinal filings remain exposed to a single Rule 702 decision, while vision-loss filings in MDL 3163 run on a separate and longer clock.

Firms with Uber inventory should model the docket on its history total and the known settlement inventory, not on a pending count that is now falling for administrative reasons.

For litigation funders and lenders

Portfolio models that use monthly JPML counts as a proxy for claimant volume will misprice registry-heavy dockets (Suboxone, AFFF) and state-heavy dockets (talc, social media). The terminations calculation above is a cheap check on whether a settlement is actually being performed: a docket with a signed master agreement and zero monthly terminations is still at the paperwork stage, and payment timelines should be assumed to run accordingly.

For defendants and their insurers

The top five dockets moved by a combined 379 actions in a month, so the largest exposures are essentially static. The movement is in the mid-sized dockets, where a single verdict or expert ruling changes the intake rate within weeks. For insurers reserving against those dockets, the pending-to-history ratio and the monthly termination figure together say more about remaining exposure than the pending count alone. Defendants in the two new spinal cord stimulator MDLs start with dockets of roughly two dozen cases each; early case management orders, Plaintiff Fact Sheet (PFS) requirements and federal Preemption (Products) motions will determine whether either grows into a four-figure docket.

For arbitration and mass-claims counsel

The JPML figures cover only court litigation. Claims that consumers and workers bring under an Arbitration Agreement never appear in them, even when a single Mass Arbitration campaign reaches the size of a mid-sized MDL. The American Arbitration Association's 2025 data, analyzed earlier this month, showed 88 mass arbitration campaigns and just under 105,000 demands. For any product or service sold under an arbitration clause, court statistics are at most half of the aggregate-claims picture.

Methodology and limits of this analysis

All November figures come from the JPML's MDL statistics report dated November 2, 2026, as rendered in search indexes of that PDF and cross-checked against secondary trackers that cite it; the report could not be fetched directly at publication. October comparisons come from the JPML's October 1, 2026 report as verified for this site's October coverage. Monthly changes are simple subtraction, and pending-share and termination figures are calculated by this desk.

Figures that could not be corroborated were omitted, including a national pending total, transferee judge and district counts, November counts for the Roundup, opioid, infant formula and valsartan dockets, and November counts for the two new spinal cord stimulator MDLs. Where the November and October rows do not reconcile (hair relaxer) or match exactly in a way worth checking (proton-pump inhibitors), the article says so rather than adjusting the numbers.

FAQ

How many MDLs are pending in November 2026?

The JPML's November 2, 2026 report lists 164 pending MDL dockets, up from 162 on October 1, 2026, after the Panel created separate Abbott and Nevro spinal cord stimulator MDLs on October 2.

What is the largest MDL in November 2026?

The Johnson & Johnson talcum powder litigation, MDL No. 2738 in the District of New Jersey, with 69,376 pending actions out of 72,060 filed. The Bard/Davol hernia mesh MDL is second with 23,299.

Why did the Uber sexual assault MDL case count drop?

About 699 actions left MDL 3084 between the October and November reports while 331 new ones were filed, cutting pending actions from 4,916 to 4,548; the exits coincide with performance of inventory settlements covering 972 federal claims disclosed in July 2026.

How many social media addiction lawsuits are pending in MDL 3047?

4,309 pending actions as of November 2, 2026, up 485 from 3,824 in October, out of 4,495 filed. California's JCCP 5255 holds thousands more cases that the federal count excludes.

How many hair relaxer lawsuits are pending in November 2026?

The JPML lists 12,743 pending actions out of 17,018 filed in MDL No. 3060, though the month-on-month gain does not fully reconcile with October's history total.

How many Ozempic and GLP-1 lawsuits are pending in November 2026?

4,082 gastrointestinal-injury actions in MDL No. 3094 and 278 vision-loss (NAION) actions in MDL No. 3163, both before Judge Karen Spencer Marston in the Eastern District of Pennsylvania.